Rosettagx.com

Rosettagx.com has Server used 151.139.128.10 IP Address with Hostname in United States. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2015-07-03 (6 years, 208 days) and hosted in Brooklyn United States, server ping response time 7 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Rosettagx keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Rosettagx reveal
2 Rosetta getty
3 Rosettagamib de3
4 Rosettagenff
5 Rosettagpcr
6 Rosettagiacco
7 Rosettagithub

Hosting Provider

Website: Rosettagx.com
Hostname: map3.hwcdn.net
Country:
NetName:
Address: see http,
Region: NY
City: Brooklyn
Postal Code: 11217
Latitude: 40.68090057373
Longitude: -73.980499267578
Area Code: 718
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain


New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   » Revo.com (14 hours ago)

   » Bobbyjonesband.com (5 hours ago)

   » 1stchoiceautosllc.com (5 hours ago)

   » Huishoubao.com (10 hours ago)

   » M1file.com (1 day ago)

   » Renhomesantalya.com (8 hours ago)

   » Napadrivertours.com (1 day ago)

Results For Websites Listing

Found 9 Websites with content related to this domain, It is result after search with search engine

RosettaGX(TM) Testing Services – Research Laboratory

Rosettagx.com   DA: 13 PA: 13 MOZ Rank: 26

Integration of molecular profiles in a longitudinal wellness profiling cohort An important aspect of precision medicine is to probe the stability in molecular profiles among healthy individuals over time.

Contact Us – RosettaGX(TM) Testing Services – Research

Rosettagx.com   DA: 13 PA: 12 MOZ Rank: 26

  • Please update your subscription plan at rss.app

Lab Management Guidelines V2.0.2019 RosettaGX Reveal

Evicore.com   DA: 15 PA: 50 MOZ Rank: 67

  • RosettaGX Reveal is a diagnostic assay that utilizes quantitative reverse transcription polymerase chain reaction (qRT-PCR) to isolate the four genetic mutations indicative of thyroidal tumor diagnosis and prognosis: BRAF and RAS point mutations and RET/PTC and PAX8/PPARγ rearrangements
  • These genetic mutations are consistently

Houston Thyroid & Endocrine Specialists

Houstonendocrine.com   DA: 24 PA: 50 MOZ Rank: 77

  • 99% NPV, 98% Sensitivity (for agreement set) RosettaGX Reveal performance was determined in a multi-center, blinded validation study
  • 99% NPV and 98% sensitivity (n=150), Bethesda Class III, IV, V) was determined, with 3/3 Pathologists agreeing on diagnosis
  • 94% success rate in obtaining results

Lab Management Guidelines V1.0.2020 RosettaGX Reveal

Evicore.com   DA: 15 PA: 50 MOZ Rank: 69

RosettaGX Reveal is a diagnostic assay that utilizes quantitative reverse transcription polymerase chain reaction (qRT-PCR) to measure levels of 24 microRNA species; these levels are then analyzed with a proprietary classifier algorithm in order to predict

Rosetta Receives Approval For RosettaGX Reveal

Technologynetworks.com   DA: 26 PA: 50 MOZ Rank: 81

  • RosettaGX Reveal is the only molecular test in the thyroid market that has been validated in a multicenter, international, blinded study using convenient, routinely prepared cytology slides
  • The assay is CLIA certified, but New York requires an additional license from the NYSDOH for CLIA-certified tests to be offered to patients in the state.

Rosetta Genomics' (ROSG) RosettaGX Reveal Receives

Streetinsider.com   DA: 21 PA: 50 MOZ Rank: 77

RosettaGX Reveal is the only molecular test in the thyroid market that has been validated in a multicenter, international, blinded study …

New York State Approves Rosetta’s Thyroid Cancer

Aacc.org   DA: 12 PA: 50 MOZ Rank: 69

  • Analytes, Tumor Markers, Regulatory/Legal
  • The New York State Department of Health has granted final approval to Rosetta Genomics for its RosettaGX Reveal, which is designed to aid in diagnosing indeterminate thyroid cases
  • Rosetta previously received conditional approval for the test in early 2016
  • The assay evaluates thyroid nodules that were

Rosetta Genomics' Thyroid Cancer Diagnostic Assay Receives

Pharmabiz.com   DA: 17 PA: 17 MOZ Rank: 42

  • RosettaGX Reveal is the only molecular test in the thyroid market that has been validated in a multicenter, international, blinded study using convenient, routinely prepared cytology slides
  • The assay is CLIA certified, but New York requires an additional license from the NYSDOH for CLIA-certified tests to be offered to patients in the state.

Recently Analyzed Sites

Revo.com (14 hours ago)

Bobbyjonesband.com (5 hours ago)

1stchoiceautosllc.com (5 hours ago)

Huishoubao.com (10 hours ago)

M1file.com (1 day ago)

Renhomesantalya.com (8 hours ago)

Trekksoft.com (1 day ago)

Tibbo.com (1 day ago)

Aimbusinesscap.com (1 seconds ago)

Tailspinbandsc.com (1 day ago)

Dungscanada.com (3 day ago)

Jfsorange.org (1 day ago)

Marloweslu.com (8 hours ago)